Full publication of randomised Scandinavian dose escalation trial for LS SCLC
45Gy / 30 Fx / 3 weeks vs 60Gy / 40 Fx / 4 weeks 2a OS 74.2% vs 48.1% Med OS 37.2 mo vs 22.6 mo Med PFS 18.6 mo vs 10.9 mo (p=0.13) Grade 3+ toxicity and SAEs BOOK APPOINTMENT First benefit of dose escalation in NSCLC / SCLC since SBRT for stage I NSCLC Discussion - Phase II - Long term OS not yet available - OS in control arm comparable to literature - Lack of PFS & LC benefit due to difficult image interpretation ? - FDG-PET staging & TV definition #DrRajeshBollam #oncologistinyashoda #hematolgist #HematoOncologist #lungcancerdoctor #radiationdose #SCLC BOOK APPOINTMENT